Chinese General Practice ›› 2022, Vol. 25 ›› Issue (14): 1772-1778.DOI: 10.12114/j.issn.1007-9572.2021.01.035
Special Issue: 肿瘤最新文章合集; 安全用药最新文章合集
• Review • Previous Articles Next Articles
Received:
2021-12-19
Revised:
2022-01-15
Published:
2022-03-24
Online:
2022-04-07
Contact:
Tieying SUN
About author:
通讯作者:
孙铁英
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.01.035
种类 | 代表药物 | |
---|---|---|
传统化疗药物 | 抗肿瘤抗生素 抗代谢药 铂类 拓扑异构酶抑制剂 蛋白酶体抑制剂 | 博来霉素 阿扎胞苷、吉西他滨、地西他滨 奥沙利铂 伊立替康 硼替佐米 |
分子靶向药物 | mTOR抑制剂 TKI抑制剂 EGFR抑制剂 ALK抑制剂 抗CD20抑制剂 | 雷帕霉素、依维莫司 西妥昔单抗、吉非替尼 克唑替尼、塞来替尼 利妥昔单抗 |
免疫治疗药物 | CTLA-4抑制剂 PD-1抑制剂 PD-L1抑制剂 | ipilimumab nivolumab,pembrolizumab durvalumab |
临床试验新药a | 抗体药物偶联物 PI3K/AKT/mTOR抑制剂 表观遗传学药物 |
Table 1 Classification of anticancer drugs inducing organizing pneumonia
种类 | 代表药物 | |
---|---|---|
传统化疗药物 | 抗肿瘤抗生素 抗代谢药 铂类 拓扑异构酶抑制剂 蛋白酶体抑制剂 | 博来霉素 阿扎胞苷、吉西他滨、地西他滨 奥沙利铂 伊立替康 硼替佐米 |
分子靶向药物 | mTOR抑制剂 TKI抑制剂 EGFR抑制剂 ALK抑制剂 抗CD20抑制剂 | 雷帕霉素、依维莫司 西妥昔单抗、吉非替尼 克唑替尼、塞来替尼 利妥昔单抗 |
免疫治疗药物 | CTLA-4抑制剂 PD-1抑制剂 PD-L1抑制剂 | ipilimumab nivolumab,pembrolizumab durvalumab |
临床试验新药a | 抗体药物偶联物 PI3K/AKT/mTOR抑制剂 表观遗传学药物 |
Figure 7 Pembrolizumab,pathology of lung biopsy under bronchoscopy:organizing pneumonia,thickening of the alveolar compartment,mild chronic inflammation
[1] |
|
[2] |
American Thoracic Society,European Respiratory Society. American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. this joint statement of the American thoracic society (ATS),and the European respiratory society (ERS) was adopted by the ATS board of directors,June 2001 and by the ERS executive committee,June 2001[J]. Am J Respir Crit Care Med,2002,165(2):277-304. DOI:10.1164/ajrccm.165.2.ats01.
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] |
|
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[45] |
|
[46] |
Cancer Therapy Evaluation Program DoCTaDNCINIoH. Common Terminology Criteria for Adverse Events,2017[EB/OL]. [2021-06-16].
|
[47] |
|
[48] |
|
[49] |
|
[50] |
|
[51] |
|
[52] |
|
[53] |
|
[54] |
|
[55] |
李珊,孙宇新,黄慧,等. 免疫检查点抑制剂相关性间质性肺疾病的诊疗进展[J]. 中华结核和呼吸杂志,2018,12(41):971-974. DOI:10.3760/cma.j.issn.1001-0939.2018.12.014.
|
[1] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[2] | XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109. |
[3] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[4] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[5] | WANG Jiaxin, ZHAO Yali. Domestic and International Assessment Tools for Medical Teamwork: a Systematic Review [J]. Chinese General Practice, 2023, 26(31): 3951-3962. |
[6] | WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733. |
[7] | YUAN Xiwei, NAN Yuemin. Research Progress of Structure, Function and Mechanism of Action of Mitofusin 2 in Liver Diseases [J]. Chinese General Practice, 2023, 26(30): 3841-3846. |
[8] | XIAO Yuqian, BAI Yanjie, WANG Yan, CHEN Shuying, CHEN Limin, SUN Kexin, WAN Jun. Research Progress of Mitochondrial Transfer in Post-stroke Cognitive Impairment [J]. Chinese General Practice, 2023, 26(30): 3833-3840. |
[9] | LIU Yu, YUE Ting, YANG Dongyu, ZHAO Zhongting, YANG Jibo, ZHU Tiantian. Research Progress on Mechanism of Autophagy in the Pathogenesis of Rheumatoid Arthritis [J]. Chinese General Practice, 2023, 26(29): 3710-3714. |
[10] | PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703. |
[11] | REN Yanfeng, LIU Shimeng, TAO Ying, CHEN Yingyao. A Systematic Review of Medication Preferences for Patients with Depression Based on Discrete Choice Experiment and Best-worst Scaling [J]. Chinese General Practice, 2023, 26(28): 3559-3564. |
[12] | TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348. |
[13] | LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341. |
[14] | CHEN Xiaofen, CHEN Yuhan, MA Juan. Recent Strides in Novel Treatments for Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(27): 3349-3354. |
[15] | ZHU Guangyu, CHENG Yuxin, LU Xuejing. Research Progress of Ocular Glymphatic System and Related Ocular Diseases [J]. Chinese General Practice, 2023, 26(26): 3330-3334. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||